Prolastin-C
Biological
Grifols Therapeutics LLC
Total Payments
$7.2M
Transactions
24,842
Doctors
6,100
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $189,774 | 46 | 0 |
| 2021 | $336,801 | 63 | 0 |
| 2020 | $254,999 | 95 | 0 |
| 2019 | $854,640 | 1,711 | 600 |
| 2018 | $2.3M | 7,998 | 3,285 |
| 2017 | $3.3M | 14,929 | 4,606 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.0M | 981 | 68.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 663 | 20.2% |
| Food and Beverage | $481,380 | 21,898 | 6.7% |
| Travel and Lodging | $211,694 | 1,222 | 2.9% |
| Consulting Fee | $55,000 | 20 | 0.8% |
| Education | $39,464 | 41 | 0.5% |
| Honoraria | $6,925 | 17 | 0.1% |
Payments by Type
Research
$5.0M
981 transactions
General
$2.3M
23,861 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens 60 mgkg and 120 mgkg of Weekly Intravenous Alpha1 Proteinase Inhibitor Human in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin D | Grifols Therapeutics LLC | $2.8M | 0 |
| An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor Human, Modified Process 60 mgkg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency | Grifols Therapeutics LLC | $1.4M | 0 |
| A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus | Grifols Therapeutics LLC | $477,236 | 0 |
| A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens 60 mgkg and 120 mgkg of Weekly Intravenous Alpha1 Proteinase Inhibitor Human in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin | Grifols Therapeutics LLC | $9,600 | 0 |
| An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor Human, Modified Process 60mgkg in Subjects With Pulmonary Empysema Due to Alpha1-Antitrypsin | Grifols Therapeutics LLC | $5,080 | 0 |
| A Multi-center, Randomized, Double-blind, Crossover Study to Assess the Safety and Pharmacokinetics of Liquid Alpha 1-Proteinase Inhibitor Human Compared to Prolastin-C in Subjects With Alpha 1-Antitrypsin Deficiency | Grifols Therapeutics LLC | $3,221 | 0 |
| An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor Human, Modified Process 60 mgkg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency | Grifols Biologicals LLC | $163.40 | 0 |
| A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens 60 mgkg and 120 mgkg of Weekly Intravenous Alpha1 Proteinase Inhibitor Human in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin D | Grifols Biologicals LLC | $43.00 | 0 |
Top Doctors Receiving Payments for Prolastin-C
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Birmingham, AL | $5.0M | 1,018 |
| Douglas Hogarth | Pulmonary Disease | Chicago, IL | $236,319 | 372 |
| , DO | Pulmonary Disease | East Setauket, NY | $157,404 | 226 |
| , DO | Pulmonary Disease | Ocean, NJ | $126,647 | 226 |
| , M.D | Pulmonary Disease | Weston, FL | $105,383 | 156 |
| , MD | Critical Care Medicine | Anderson, IN | $92,330 | 107 |
| , MD | Pulmonary Disease | Eglin Afb, FL | $79,024 | 155 |
| , MD | Critical Care Medicine | Phoenix, AZ | $66,086 | 129 |
| , M.D | Pulmonary Disease | Hazard, KY | $56,172 | 115 |
| , MD | Internal Medicine | Pensacola, FL | $55,979 | 99 |
| , MD | Pulmonary Disease | San Antonio, TX | $45,461 | 70 |
| , M.D | Internal Medicine | Starkville, MS | $36,567 | 64 |
| , M.D | Pulmonary Disease | Los Angeles, CA | $34,536 | 61 |
| , M.D | Pulmonary Disease | Sarver, PA | $28,520 | 39 |
| , M.D | Hospitalist | Chesapeake, VA | $28,484 | 35 |
| , MD | Critical Care Medicine | Richmond, VA | $27,578 | 39 |
| , M.D | Critical Care Medicine | Fall River, MA | $26,979 | 66 |
| , M.D | Pulmonary Disease | Sacramento, CA | $24,844 | 33 |
| , M.D | Pulmonary Disease | Shaker Heights, OH | $23,211 | 28 |
| , MD | Pulmonary Disease | Las Vegas, NV | $22,888 | 32 |
| , MD | Pulmonary Disease | Phoenix, AZ | $22,528 | 44 |
| , MD | Pulmonary Disease | Guaynabo, PR | $22,222 | 29 |
| , MD | Pulmonary Disease | Pittsburgh, PA | $22,004 | 27 |
| Michael Zlupko | Pulmonary Disease | Altoona, PA | $21,732 | 53 |
| , M.D | Pulmonary Disease | Brewster, NY | $19,157 | 35 |
Ad
Manufacturing Companies
- Grifols Therapeutics LLC $4.7M
- Grifols USA, LLC $2.2M
- Grifols Shared Services North America, Inc. $273,648
- Grifols Canada Ltd. $23,562
- Grifols Biologicals LLC $206.40
Product Information
- Type Biological
- Total Payments $7.2M
- Total Doctors 6,100
- Transactions 24,842
About Prolastin-C
Prolastin-C is a biological associated with $7.2M in payments to 6,100 healthcare providers, recorded across 24,842 transactions in the CMS Open Payments database. The primary manufacturer is Grifols Therapeutics LLC.
Payment data is available from 2017 to 2022. In 2022, $189,774 was paid across 46 transactions to 0 doctors.
The most common payment nature for Prolastin-C is "Unspecified" ($5.0M, 68.8% of total).
Prolastin-C is associated with 8 research studies, including "A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens 60 mgkg and 120 mgkg of Weekly Intravenous Alpha1 Proteinase Inhibitor Human in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin D" ($2.8M).